Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6121900 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL16824585 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL16856331 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL18177046 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL903505 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL12294932 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL21863336 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL20689888 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL22811006 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL8749334 | 1.00 | PREP (0.68) | PREPCHRM2CHRM1CHRM3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4267560-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022140325-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3083562-B1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | PTGER4, PTGER1, GPR4 | PREP 3160/4885CHRM2 109/4885CHRM1 80/4885 |
| US-20250002471-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | PREP 2811/4885CHRM2 1812/4885CHRM1 2739/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | PREP 2003/4885CHRM2 2125/4885CHRM1 2246/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | PREP 2003/4885CHRM2 2125/4885CHRM1 2246/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | PREP 2056/4885CHRM2 1569/4885CHRM1 2149/4885 |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | PREP 59/4885CHRM2 2121/4885CHRM1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.